Colgate-Palmolive (CL) Stock Forecast & Price Target

Colgate-Palmolive is attractive because its international business has consistently delivered mid- to high-single-digit organic growth, with Europe adding about 300 bps of toothpaste share since 2016 and emerging markets providing nearly half of sales through a broad 200-country footprint. The company also benefits from Hill’s, which contributes almost one-fourth of sales and supports a premium, science-led pet nutrition platform that has remained resilient even as the broader category is flat to slightly down. While North America has been a drag, management’s ability to expand margins, execute its European-style two-brand playbook, and capture up to $500–575 million in annual savings supports earnings growth and a stronger long-term mix.

Colgate-Palmolive is under pressure because its North American business has lagged HPC peers by about 250 bps over the last 8 quarters, with the region down roughly 2% as pricing missteps, weaker marketing investment, and mix damage from trading down have hurt share. Its toothpaste portfolio also sits at a more than 50% discount to Haleon’s and a 28% discount to P&G’s, leaving it underindexed to premium and super-premium tiers where pricing power is strongest, while excessive line extensions have failed to create incremental value. Although international momentum has been impressive, that strength is offset by currency volatility, stepped-up emerging-market competition, and margin pressure from roughly $300M of 2026 incremental costs, supporting a downside case with only about 2.7% top-line CAGR and peak margins near 20% through 2035.